9,10-seco- Cyclopentanohydrophenanthrene Ring System (e.g., Vitamin D, Etc.) Doai Patents (Class 514/167)
-
Patent number: 8664206Abstract: Compounds of formula I are provided where X1, X2, and X3 are independently selected from H or hydroxy protecting groups. Such compounds may be used in preparing pharmaceutical compositions and are useful in treating a variety of biological conditions.Type: GrantFiled: January 6, 2012Date of Patent: March 4, 2014Assignee: Wisconsin Alumni Research FoundationInventors: Hector F. DeLuca, Agnieszka Flores, Pawel Grzywacz, Lori A. Plum, Margaret Clagett-Dame, James B. Thoden, Hazel M. Holden
-
Patent number: 8658206Abstract: The invention relates to the finding that very favorable pharmacokinetic characters are obtained by combining two strontium salts in one pharmaceutical composition. The present invention relates in one aspect to a pharmaceutical composition comprising at least two strontium salts for use as a medicament, and in particular for the treatment and prevention of bone disorders such as osteoporosis. The composition preferably comprises strontium carbonate and strontium chlorides. Further included may be a vitamin D compound, preferably vitamin D3.Type: GrantFiled: June 24, 2005Date of Patent: February 25, 2014Assignee: Mokwalo SAInventor: John N. Hvarre Christensen
-
Publication number: 20140038925Abstract: The present invention provides a compound which functions as a selective vitamin D receptor modulator and has action-selectivity or tissue-selectivity such that it does not induce hypercalcemia but causes other effects. There is provided a compound represented by formula (I), a solvate thereof or a prodrug thereof. wherein m and n each independently represent 1 or 0; R represents a hydrogen atom or an alkyl group; Y represents an ethane-1,1-diyl group or an ethyne-1,2-diyl group; and Z1 represents a hydrogen atom and Z2 represents a hydroxyalkoxy group, or Z1 and Z2 jointly form a methylene group.Type: ApplicationFiled: March 1, 2012Publication date: February 6, 2014Inventors: Makoto Makishima, Sachiko Yamada, Antonio Mourino, Hiroaki Tokiwa, Takeru Kudo, Yusuke Watarai, Kazuki Maekawa
-
Publication number: 20140037577Abstract: The present invention includes methods and compositions for the treatment and prevention of protozoal parasitic infections utilizing Diindolylmethane-related indoles. Additive and synergistic interaction of Diindolylmethane-related indoles with other known anti-parasitic and pro-apoptotic agents is believed to permit more effective therapy and prevention of protozoal parasitic infections. The methods and compositions described provide new treatment of protozoal parasitic diseases of mammals and birds including malaria, leishmaniasis, trypanosomiasis, trichomoniasis, neosporosis and coccidiosis.Type: ApplicationFiled: October 10, 2013Publication date: February 6, 2014Inventor: Michael A. Zeligs
-
Patent number: 8642579Abstract: This invention discloses 1-desoxy-2-methylene-19-nor-vitamin D analogs, and specifically (20S)-25-hydroxy-1-desoxy-2-methylene-19-nor-vitamin D3 and pharmaceutical uses therefor. This compound exhibits relatively high binding activity and pronounced activity in arresting the proliferation of undifferentiated cells and inducing their differentiation to the monocyte thus evidencing use as an anti-cancer agent especially for the treatment or prevention of leukemia, colon cancer, breast cancer, skin cancer or prostate cancer.Type: GrantFiled: September 30, 2010Date of Patent: February 4, 2014Assignee: Wisconsin Alumni Research FoundationInventors: Hector F. DeLuca, Katarzyna M. Barycka, Izabela Sibilska, Lori A. Plum, Margaret Clagett-Dame, Rafal Barycki, Rafal R. Sicinski, Katarzyna Plonska-Ocypa
-
Publication number: 20140031321Abstract: The current invention is directed to methods of inducing the negative chemotaxis of a migratory cell comprising contacting the cell with a compound selected from the group consisting of idebenone, benazepril, rolipram, moxonidine, lamivudine, loxoprofen, terbinafine, synephrine, 6-aminoindazole, and a Vitamin D analog, or a pharmaceutically acceptable salt of any of thereof.Type: ApplicationFiled: January 14, 2013Publication date: January 30, 2014Applicant: CELTAXSYS, INC.Inventor: Erica Brook Goodhew
-
Publication number: 20140030359Abstract: The present invention provides methods and compositions for treating thyroid-related medical conditions. Many thyroid-related medical conditions exist that go undiagnosed and untreated. These conditions may be prevented and treated with reduced folates and vitamin B12. Administration of reduced folates and vitamin B12 will prevent or treat cerebrospinal folate deficiency, which is linked to thyroid-related medical conditions. Administration of reduced folates and vitamin B12 will also prevent or treat conditions associated with masked megaloblastic anemia and hypothyroidism, and other conditions brought upon through improper thyroid function. Additionally, it is commonplace to treat many thyroid conditions with anti-thyroid drugs or thyroid stimulating drugs. This practice alone is also responsible for causing, or not beneficially addressing, adverse conditions that can be prevented or treated through the methods and compositions discussed herein.Type: ApplicationFiled: October 1, 2013Publication date: January 30, 2014Inventor: Linzy O. Scott, III
-
Publication number: 20140031322Abstract: A medicine composition contains vitamin D and metformin, wherein vitamin D comprises vitamin D2, vitamin D3, alphacalcidol, calcifediol, calcitriol, and dihydrotachysterol. The composition can be used in the preparation of a medicine for treating and/or preventing a polyp and cancer in large intestine.Type: ApplicationFiled: August 17, 2011Publication date: January 30, 2014Applicant: GUANGDONG TAIHE MEDICINE SCIENCE & TECHNOLOGY CO., LTD.Inventor: Fulin Fan
-
Publication number: 20140024625Abstract: This invention relates to methods for improving changing the quality of the meibum composition of the meibomian glands to enhance or improve the lipid layer of the tear and increase tear breakup time by way of elevating the omega-3 index in patients suffering from symptoms of dry eye, posterior blepharitis, and/or meibomian gland dysfunction. The methods comprise administering a supplementation of omega-3 fatty acids to a patient having an inflamed meibomian gland so as to facilitate an increase in the amount of omega-3's acting as an anti-inflammatory and, respectively, decrease the amount of omega-6?s (arachidonic acid) acting as an inflammatory in the composition of the meibum, thereby normalizing the lipid layer of the tear and effectively reducing the associated symptoms. In certain embodiments, the supplementation of omega-3's comprises the esterified or re-esterified triglyceride form.Type: ApplicationFiled: March 12, 2013Publication date: January 23, 2014Inventors: S. Gregory Smith, Michael B. Gross, Olav E. Sandnes
-
Publication number: 20140024626Abstract: The present invention relates to the use canthaxanthin and/or 25-hydroxy vitamin D3 (25-OH D3) for improving breeder hatchability and fertility and for lowering embryo mortality in poultry. More particularly, the invention relates to the use of Canthaxanthin and/or 25-hydroxy canthaxanthin in the manufacture of a food or veterinary composition for improving hatchability in poultry.Type: ApplicationFiled: September 23, 2013Publication date: January 23, 2014Applicant: DSM IP ASSETS B.V.Inventors: Jose-Maria HERNANDEZ, Gilbert WEBER
-
Publication number: 20140017196Abstract: Methods and compositions containing a phorbol ester or a derivative of a phorbol ester are provided for the treatment of chronic and acute conditions. Such conditions may be caused by disease, be symptoms or sequelae of disease. Chronic and acute conditions may be due to viral infections such as HIV and AIDS, neoplastic diseases stroke, kidney disease, urinary incontinence, autoimmune disorders, Parkinson's disease, prostate hypertrophy, aging, or the treatment of such diseases. Additional compositions and methods are provided which employ a phorbol ester or derivative compound in combination with at least one additional agent to yield more effective treatment tools against acute and chronic conditions in mammalian subjects.Type: ApplicationFiled: September 16, 2013Publication date: January 16, 2014Applicant: BIOSUCCESS BIOTECH CO., LTD.Inventors: Zheng Tao HAN, Hung-Fong CHEN
-
Publication number: 20140018330Abstract: The present invention relates to the use of a 2,5-dihydroxybenzene derivative of formula (I) or a pharmaceutically acceptable salt, solvate, isomer, or prodrug thereof for the treatment and/or prophylaxis of, inter alia, rosacea.Type: ApplicationFiled: July 9, 2013Publication date: January 16, 2014Inventors: Pedro Cuevas Sànchez, Guillermo Gimenez Gallego, Inigo Saenz de Tejada Gorman, Javier Angulo Frutos, Serafin Valverde Lopez, Antonio Romero Garrido, Rosa Maria Lozano Puerto
-
Publication number: 20140018332Abstract: Oral and topical pharmaceutical compositions, kits and methods of treatment thereof for treating various skin disorder including acne, psoriasis, ichthyosis, photoaging, photodamaged skin, and, skin cancer.Type: ApplicationFiled: September 23, 2013Publication date: January 16, 2014Applicant: Wisconsin Alumni Research FoundationInventors: Margaret Clagett-Dame, Hector F. DeLuca, Nircaq J. Nieves, Lori A. Plum, Mary E. Kaiser
-
Patent number: 8629128Abstract: A pharmaceutical aerosol foam composition, comprising: an effective amount of a pharmaceutically active ingredient, wherein said pharmaceutically active ingredient is a vitamin or analogue thereof; an occlusive agent; an aqueous solvent; an organic cosolvent; wherein the pharmaceutically active ingredient is insoluble in both water and the occlusive agent; and the occlusive agent being present in an amount sufficient to form an occlusive layer on the skin, in use. In a second embodiment, an oil-in water emulsion having a vitamin, an occlusive agent; an aqueous solvent; and an organic cosolvent, wherein the occlusive agent is present in an amount sufficient to form an occlusive layer on the skin.Type: GrantFiled: September 20, 2012Date of Patent: January 14, 2014Assignee: Stiefel West Coast, LLCInventors: Richard Buchta, Robert James Houlden, Maria Graziella Larm, Leon Loupenok, Rose Ye
-
Publication number: 20140011778Abstract: Compounds of Formula I are provided where R1 and R2 are independently selected from H or hydroxy protecting groups. Such compounds may be used in preparing pharmaceutical compositions and are useful in treating a variety of biological conditions.Type: ApplicationFiled: September 12, 2013Publication date: January 9, 2014Applicant: Wisconsin Alumni Research FoundationInventors: Hector F. DeLUCA, Margaret Clagett-Dame, Lori A. Plum, Agnieszka Glebocka, Rafal Sicinski
-
Use of 2-Methylene-19-Nor-(20S)-1alpha,25-Dihydroxyvitamin D3 to Treat Secondary Hyperparathyroidism
Publication number: 20140005152Abstract: Disclosed are methods of administering 2-methylene-19-nor-(20S)-1?,25-dihydroxyvitamin D3 to treat and/or prevent secondary hyperparathyroidism and/or its accompanying symptoms in a subject having or at risk for developing secondary hyperparathyroidism.Type: ApplicationFiled: March 14, 2013Publication date: January 2, 2014Applicant: Wisconsin Alumni Research FoundationInventors: Hector F. DeLuca, Lori A. Plum, Julia B. Zella, Wendy Bedale, Margaret Clagett-Dame -
Publication number: 20130344061Abstract: Provided herein are methods, kits, and pharmaceutical compositions that include a PI3 kinase inhibitor for treating lupus, a fibrotic condition, or inflammatory myopathies and other conditions (e.g., skin conditions).Type: ApplicationFiled: March 15, 2013Publication date: December 26, 2013Applicant: INFINITY PHARMACEUTICALS, INC.Inventors: Vito J. PALOMBELLA, David G. WINKLER
-
Patent number: 8614202Abstract: This invention discloses 2?-methyl and 2?-methyl analogs of 19,26,27-trinor-(20S)-1?-hydroxyvitamin D3 and pharmaceutical uses therefor. These compounds exhibit pronounced activity in arresting the proliferation of undifferentiated cells and inducing their differentiation to the monocyte thus evidencing use as an anti-cancer agent and for the treatment of skin diseases such as psoriasis as well as skin conditions such as wrinkles, slack skin, dry skin and insufficient sebum secretion. These compounds also have little, if any, calcemic activity and therefore may be used to treat autoimmune disorders or inflammatory diseases in humans as well as renal osteodystrophy. These compounds may also be used for the treatment or prevention of obesity.Type: GrantFiled: September 18, 2012Date of Patent: December 24, 2013Assignee: Wisconsin Alumni Research FoundationInventors: Hector F. DeLuca, Lori A. Plum, Pawel K. Grzywacz, Margaret Clagett-Dame
-
Publication number: 20130336918Abstract: Compounds having activity as phosphate transport inhibitors, more specifically, inhibitors of intestinal apical membrane Na/phosphate co-transport, are disclosed. The compounds have the following structure (I): including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein X, Y and A are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.Type: ApplicationFiled: January 4, 2013Publication date: December 19, 2013Applicant: ARDELYX, INC.Inventor: Ardelyx, Inc.
-
Publication number: 20130336919Abstract: Compounds having activity as phosphate transport inhibitors, more specifically, inhibitors of intestinal apical membrane Na/phosphate co-transport, are disclosed. The compounds have the following structure (I): including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein X, Y, R1 and R2 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.Type: ApplicationFiled: January 4, 2013Publication date: December 19, 2013Applicant: ARDELYX, INC.Inventor: Ardelyx, Inc.
-
Publication number: 20130336920Abstract: Compounds having activity as phosphate transport inhibitors, more specifically, inhibitors of intestinal apical membrane Na/phosphate co-transport, are disclosed. The compounds have the following structure (I): including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein X, Y, A, R1 and R2 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.Type: ApplicationFiled: January 4, 2013Publication date: December 19, 2013Applicant: ARDELYX, INC.Inventor: Ardelyx, Inc.
-
Publication number: 20130336921Abstract: Compounds having activity as phosphate transport inhibitors, more specifically, inhibitors of intestinal apical membrane Na/phosphate co-transport, are disclosed. The compounds have the following structure (I): including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein X, Y and A are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.Type: ApplicationFiled: January 4, 2013Publication date: December 19, 2013Applicant: ARDELYX, INC.Inventors: Jason G. Lewis, Jeffrey W. Jacobs, Nicholas Reich, Michael R. Leadbetter, Noah Bell, Han-Ting Chang, Tao Chen, Marc Navre, Dominique Charmot, Christopher Carreras, Eric Labonte
-
Patent number: 8609643Abstract: This invention discloses 2-methylene-(20S,25R)-19,26-dinor-vitamin D analogs, and specifically 2-methylene-(20S,25R)-19,26-dinor-1?,25-dihydroxyvitamin D3, and pharmaceutical uses therefor. This compound exhibits pronounced activity in arresting the proliferation of undifferentiated cells and inducing their differentiation to the monocyte thus evidencing use as an anti-cancer agent and for the treatment of skin diseases such as psoriasis as well as skin conditions such as wrinkles, slack skin, dry skin and insufficient sebum secretion. This compound also has little, if any, calcemic activity and therefore may be used to treat autoimmune disorders or inflammatory diseases in humans as well as renal osteodystrophy. This compound may also be used for the treatment or prevention of obesity.Type: GrantFiled: December 24, 2008Date of Patent: December 17, 2013Assignee: Wisconsin Alumni Research FoundationInventors: Hector F. DeLuca, Margaret Clagett-Dame, Lori A. Plum, Grazia Chiellini, Pawel Grzywacz
-
Publication number: 20130330423Abstract: The invention is directed to a composition for the use to increase joint stability or postural stability, wherein said composition comprises branched chain amino acids. It is further directed to the use of branched chain amino acids for the preparation of a food supplement or medicament for the prophylaxis and/or treatment of joint and/or postural instability.Type: ApplicationFiled: February 3, 2012Publication date: December 12, 2013Applicant: Merck Patent GmbHInventor: Claudia Scholz
-
Patent number: 8604008Abstract: Compounds of formula I are provided where X1 and X2 are independently selected from H or hydroxy protecting groups. Such compounds may be used in preparing pharmaceutical compositions and are useful in treating a variety of biological conditions.Type: GrantFiled: November 18, 2005Date of Patent: December 10, 2013Assignee: Wisconsin Alumni Research FoundationInventors: Hector F. DeLuca, Lori A. Plum, Margaret Clagett-Dame
-
Patent number: 8604009Abstract: Compounds of formula I are provided where X1, X2 and X3 are independently selected from H or hydroxy protecting groups. Such compounds may be used in preparing pharmaceutical compositions and are useful in treating a variety of biological conditions.Type: GrantFiled: March 22, 2011Date of Patent: December 10, 2013Assignee: Wisconsin Alumni Research FoundationInventors: Hector F. DeLuca, Agnieszka Flores, Pawel Grzywacz, Lori A. Plum, Margaret Clagett-Dame
-
Publication number: 20130324504Abstract: The present invention is directed to pharmaceutical compositions comprising antispasmodic C4-C8aliphatic-1,2-diols and C4-C8aliphatic-1,2,3-triols and their use to relieve the spasms associated with pain. These agents may be administered topically or orally and may be combined with anti-inflammatory agents such as a non-steroidal anti-inflammatory drug or a corticosteroid. Administration of the C4-C8aliphatic-1,2-diols and C4-C8aliphatic-1,2,3-triols with vitamin D3 is indicated for conditions such as bone loss, weight gain and autoimmune diseases such as lupus and rheumatoid arthritis.Type: ApplicationFiled: March 13, 2013Publication date: December 5, 2013Inventor: Priti Sanghvi Shah
-
Publication number: 20130324505Abstract: Described herein are assays directed to determining the level of bioavailable or free vitamin D in a blood sample in a subject. The values determined for bioavailable or free vitamin D indicate whether the subject suffers from insufficient levels of vitamin D. Also described herein are methods of treatment for vitamin D insufficiency.Type: ApplicationFiled: June 14, 2013Publication date: December 5, 2013Inventors: Ravi Thadhani, S. Ananth Karumanchi, Anders Hayden Berg, Ishir Bhan
-
Patent number: 8592401Abstract: Methods and compositions comprising 1,25-dihydroxyvitamin D2 are disclosed. A method for lowering or maintaining lowered serum parathyroid hormone in human patients including administering to said patients an effective amount of 1,25-dihydroxyvitamin D2 to lower or maintain lowered serum parathyroid hormone levels is disclosed. Dosage forms and dosing regimens are also disclosed.Type: GrantFiled: April 25, 2008Date of Patent: November 26, 2013Assignees: Proventiv Therapeutics, LLC, Cytochroma Inc.Inventors: P. Martin Petkovich, Charles W. Bishop, Eric J. Messner, Keith H. Crawford
-
Publication number: 20130309200Abstract: New imidazo[1,2-b]pyridazine and imidazo[4,5-b]pyridine derivatives having the chemical structure of formula (I) are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Janus Kinases (JAK).Type: ApplicationFiled: November 24, 2011Publication date: November 21, 2013Applicant: ALMIRALL, S.A.Inventors: Jacob Gonzalez Rodriguez, Bernat Vidal Juan, Laura Vidal Gispert, Jordi Bach Taña
-
Publication number: 20130296284Abstract: An oil in water microemulsion or sub-micron emulsion composition for dermal delivery of at least one pharmaceutically active ingredient, is provided. The composition includes an oil phase dispersed throughout a water phase, the oil phase including at least one member selected from the group consisting of an animal oil, a mineral oil, a vegetable oil, a silane member, a siloxane, an ester, a fatty acid, a fat, a halogen compound, and an alkoxylated alcohol; and at least one lipophilic surfactant, the water phase including at least one hydrophilic surfactant, water and optionally a non-surfactant amphiphilic compound, the weight ratio of the at least one hydrophilic surfactant to the at least one lipophilic surfactant being approximately 9.0:1.0 to 2.0:3.0.Type: ApplicationFiled: April 30, 2013Publication date: November 7, 2013Applicant: STIEFEL RESEARCH AUSTRALIA PTY LTDInventor: STIEFEL RESEARCH AUSTRALIA PTY LTD
-
Publication number: 20130295202Abstract: Methods for facilitating joint immobilization or fusion using selective estrogen receptor modulator (SERM) such as raloxifene are disclosed. The SERM may be administered systemically or locally. In conjunction with SERM, other therapeutic agents such as calcium, vitamin D, bone morphogenetic protein may be administered simultaneously. The method can similarly be applied to facilitate bone repair, bone healing, and connective tissue healing processes in a patient.Type: ApplicationFiled: July 3, 2013Publication date: November 7, 2013Inventor: John G. Stark
-
Publication number: 20130295089Abstract: In certain aspects, the present invention provides compositions and methods for promoting bone growth and increasing bone density.Type: ApplicationFiled: July 11, 2013Publication date: November 7, 2013Inventors: John Knopf, Jasbir Seehra
-
Publication number: 20130295179Abstract: The present application relates to compositions for use in a method of treating and/or preventing mental and behavioral disorders and/or improving mental health and cognitive functions in a subject, comprising: a) Docosahexaenoic acid (DHA) and/or the pharmaceutically acceptable derivatives and/or precursors thereof; b) Eicosapentaenoic acid (EPA) and/or the pharmaceutically acceptable derivatives and/or precursors thereof; c) ?-linolenic acid (GLA) and/or the pharmaceutically acceptable derivatives and/or precursors thereof; and at least a psychostimulant compound selected among methylphenidate HCl, atomoxetine, amphetamine, gamma-hydroxybutyrate, dextroamphetamine, sibutramine, methylenedioxymethamphetamine, and/or an anxiolytic compound selected among fluoxatine, sertraline, paroxetine, fluoroxamine, citralopram, venlafaxine, bupropion, nefazodone, and mirtazapine.Type: ApplicationFiled: April 12, 2013Publication date: November 7, 2013Inventors: Christian TERREAUX, Eleonora HOMBERGER, Burkhard KRIWET, Eduardo BARRAGAN PEREZ
-
Publication number: 20130296282Abstract: The invention describes compositions and methods of use for 2,5-dihydroxybenzene sulfonic acid compounds and pharmaceutically acceptable salts thereof. The invention provides methods for (a) treating skin cancer; (b) treating cancer of the organs; (c) treating leukemia; (d) improving the efficacy of chemotherapy, radiation therapy and/or cancer immunotherapy; (e) treating rosacea; and (f) treating psoriasis by administration of a composition comprising at least one 2,5-dihydroxybenzene sulfonic acid compound or a pharmaceutically acceptable salt thereof, and, optionally at least one therapeutic agent. Also disclosed are compositions comprising administration of at least one 2,5-dihydroxybenzene sulfonic acid compound, or a pharmaceutically acceptable salt thereof, and, at least one therapeutic agent.Type: ApplicationFiled: July 9, 2013Publication date: November 7, 2013Inventor: Pedro Cuevas Sànchez
-
Publication number: 20130295083Abstract: A method of treating islet cell transplant patients is described herein. The method comprises the steps of a) identifying an islet cell transplant patient, b) treating the patient with 2AMD or 2AMD analog and c) observing a prolonged period of normal glycemia is disclosed. A composition for treatment of islet cell transplant patient is disclosed as well, wherein the composition comprises 50-400 ng/day of 2AMD or 2AMD analog.Type: ApplicationFiled: February 20, 2013Publication date: November 7, 2013Applicant: Wisconsin Alumni Research FoundationInventors: Hector F. DeLuca, Carol M. Kiekhaefer
-
Patent number: 8575137Abstract: The invention relates to a formulation comprising formoterol and budesonide for use in the treatment of respiratory diseases. The composition further contains HFA 227, PVP and PEG, preferably PVP K25 and PEG 1000.Type: GrantFiled: March 5, 2012Date of Patent: November 5, 2013Assignee: AstraZeneca ABInventors: Nayna Govind, Maria Marlow
-
Patent number: 8575136Abstract: Compounds of formula I are provided where X1 and X2 are independently selected from H or hydroxy protecting groups. Such compounds are used in preparing pharmaceutical compositions and are useful in treating a variety of biological conditions.Type: GrantFiled: April 6, 2007Date of Patent: November 5, 2013Assignee: Wisconsin Alumni Research FoundationInventors: Hector F. DeLuca, Lori A. Plum, Margaret Clagett-Dame, Rafal Barycki
-
Patent number: 8575171Abstract: The present invention provides methods and compositions for treating thyroid-related medical conditions. Many thyroid-related medical conditions exist that go undiagnosed and untreated. These conditions may be prevented and treated with reduced folates and vitamin B12. Administration of reduced folates and vitamin B12 will prevent or treat cerebrospinal folate deficiency, which is linked to thyroid-related medical conditions. Administration of reduced folates and vitamin B12 will also prevent or treat conditions associated with masked megaloblastic anemia and hypothyroidism, and other conditions brought upon through improper thyroid function. Additionally, it is commonplace to treat many thyroid conditions with anti-thyroid drugs or thyroid stimulating drugs. This practice alone is also responsible for causing, or not beneficially addressing, adverse conditions that can be prevented or treated through the methods and compositions discussed herein.Type: GrantFiled: November 28, 2012Date of Patent: November 5, 2013Inventor: Linzy O. Scott, III
-
Patent number: 8563053Abstract: A composition and method for treating a bone condition of an animal. The composition includes a nanoformulation of active ingredients. The active ingredients include Lepidium Sativum or other Lepidium extracts, calcium, vitamin D, and antioxidants. The method for treating a bone condition includes introducing the composition into the animal.Type: GrantFiled: October 27, 2010Date of Patent: October 22, 2013Inventors: Shaker A. Mousa, Mohammed H. Qari, Mohammed S. Ardawi
-
Publication number: 20130274197Abstract: The present invention provides a family of benzodiazepinone compounds and pharmaceutical compositions thereof. The present invention also provides methods of treating certain skin conditions, e.g., atopic dermatitis, rosacea, or psoriasis, by administering a benzodiazepinone and methods of reducing the proliferation of keratinocyte cells by exposing such cells to a benzodiazepinone.Type: ApplicationFiled: June 5, 2013Publication date: October 17, 2013Inventor: Gary D. Glick
-
Publication number: 20130252927Abstract: The present invention relates to treating/preventing conditions associated with an increased level of eotaxin in a human with 25-hydroxyvitamin D3 (calcifediol). Optionally, vitamin D3 may be used together with 25-hydroxyvitamin D3.Type: ApplicationFiled: December 5, 2011Publication date: September 26, 2013Applicant: DSM IP ASSETS, B.V.Inventors: Stephanie Krammer-Lukas, Elisabeth Stoecklin, Joseph Schwager, Swen Wolfram
-
Publication number: 20130244986Abstract: Embodiments of the invention generally relate to pharmaceutical compositions containing at least one caffeic acid compound and methods for the topical treatment of proliferative and inflammatory skin disorders such as plaque psoriasis, atopic dermatitis, and other disorders. In some embodiments, the topical treatment includes applications of the pharmaceutical composition containing at least one caffeic acid compound or a mixture of caffeic acid compounds such as caffeic acid ester compounds, caffeic acid amide compounds, analogues thereof, derivatives thereof, salts thereof, or mixtures thereof. The pharmaceutical composition or topical dosage may contain the caffeic acid compound at a concentration by weight within a range from about 0.01% to about 20%, preferably, from about 0.1% to about 15%, preferably, from about 1% to about 10%, more preferably, from about 3% to about 7%, and more preferably, from about 4% to about 6%.Type: ApplicationFiled: April 26, 2013Publication date: September 19, 2013Applicant: Moleculin LLCInventors: Waldemar Priebe, Charles Conrad, Timothy Madden
-
Patent number: 8535659Abstract: The present invention relates to different nutritional supplements to be administered to, or taken by, pregnant women during the first, second and third trimesters of pregnancy.Type: GrantFiled: May 21, 2009Date of Patent: September 17, 2013Assignee: Argent Development Group, LLCInventors: John C. Morrison, Kenneth R. Greathouse
-
Patent number: 8535660Abstract: The present invention relates to different nutritional supplements to be administered to, or taken by, pregnant women during the first, second and third trimesters of pregnancy.Type: GrantFiled: November 7, 2011Date of Patent: September 17, 2013Assignee: Argent Development Group, LLCInventors: John C. Morrison, Kenneth R. Greathouse
-
Publication number: 20130236540Abstract: Methods and compositions for treating 25-hydroxyvitamin D insufficiency and deficiency in a patient are described herein. The method includes orally administering to the patient a delayed, sustained release formulation including a first ingredient selected from the group consisting of 25-hydroxyvitamin D2, 25-hydroxyvitamin D3, or a combination of 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3, or it includes gradually administering to the patient a sterile intravenous formulation including a first ingredient selected from the group consisting of 25-hydroxyvitamin D2, 25-hydroxyvitamin D3, or a combination of 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3.Type: ApplicationFiled: March 22, 2013Publication date: September 12, 2013Inventors: Charles W. Bishop, Keith H. Crawford, Eric J. Messner
-
Publication number: 20130236511Abstract: The present invention provides methods for impregnating a porous carrier with an active pharmaceutical ingredient (“AP”), the methods comprising steps: a) dissolving at least one API in a solvent to form an API solution; b) contacting a porous carrier with the at least one API of step (a) in a contactor to form an API impregnated porous carrier; and c) drying the at least one API impregnated porous carrier.Type: ApplicationFiled: August 19, 2011Publication date: September 12, 2013Applicant: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEYInventors: Fernando J. Muzzio, Benjamin J. Glasser, Plamen I. Grigorov
-
Patent number: 8519169Abstract: A method of purifying 1?-hydroxy-20-methyl-2-methylene-19,24,25,26,27-pentanorvitamin D3 to obtain 1?-hydroxy-20-methyl-2-methylene-19,24,25,26,27-pentanorvitamin D3 in crystalline form. The method includes the steps of preparing a solvent of either ethyl formate or a mixture of ethyl formate and hexane, dissolving a product containing 1?-hydroxy-20-methyl-2-methylene-19,24,25,26,27-pentanorvitamin D3 to be purified in the solvent, cooling the solvent and dissolved product below ambient temperature for a sufficient amount of time to form a precipitate of 1?-hydroxy-20-methyl-2-methylene-19,24,25,26,27-pentanorvitamin D3 crystals, and recovering the 1?-hydroxy-20-methyl-2-methylene-19,24,25,26,27-pentanorvitamin D3 crystals.Type: GrantFiled: August 17, 2012Date of Patent: August 27, 2013Assignee: Wisconsin Alumni Research FoundationInventors: Hector F. DeLuca, Agnieszka Glebocka, James B. Thoden, Hazel M. Holden
-
Patent number: 8518917Abstract: This invention discloses 2-methylene-19-nor-vitamin D analogs, and specifically (20S)-25-hydroxy-2-methylene-19-nor-vitamin D3 and (20R)-25-hydroxy-2-methylene-19-nor-vitamin D3, as well as pharmaceutical uses therefor. These compounds exhibit relatively high binding activity and pronounced activity in arresting the proliferation of undifferentiated cells and inducing their differentiation to the monocyte thus evidencing use as an anti-cancer agent especially for the treatment or prevention of osteosarcoma, leukemia, colon cancer, breast cancer, skin cancer or prostate cancer. Although these compounds have relatively low calcemic activities they may also be useful in the treatment of bone diseases due to their ability to act as prodrugs in vivo.Type: GrantFiled: October 21, 2011Date of Patent: August 27, 2013Assignee: Wisconsin Alumni Research FoundationInventors: Hector F. DeLuca, Izabela Sibliska, Lori A. Plum, Margaret Clagett-Dame, Rafal R. Sicinski, Katarzyna M. Barycka, Katarzyna Plonska-Ocypa, Rafal Barycki
-
Publication number: 20130216498Abstract: New imidazopyridine derivatives having the chemical structure of formula (I) are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Janus Kinases (JAK).Type: ApplicationFiled: December 23, 2010Publication date: August 22, 2013Inventors: Paul Robert Eastwood, Jacob Gonzales Rodriguez, Jordi Bach Taña, Lluis Miquel Pages Santacana, Joan Taltavull Moll, Juan Francisco Caturla Javaloyes, Victor Giulio Matassa